Image source: The Motley Fool.

DATE

Thursday, Aug. 13, 2026 at 4:30 p.m. ET

CALL PARTICIPANTS

• President and Chief Executive Officer-Sabrina Martucci Johnson
• Chief Accounting Officer-MarDee J. Haring-Layton

TAKEAWAYS

• Revenue -- $200,000, compared to a negative $21,000 in the same period last year, reflecting an accounting adjustment related to Vagisil royalties in the prior year.
• Net Loss -- $3 million, representing an improvement from a loss of $4 million in the second quarter of 2025, partially attributed to increased contra-R&D offsets and disciplined capital allocation.
• Cash and Cash Equivalents -- $12.6 million as of June 30, 2026, intended to support ongoing commercial launches and clinical development.
• Working Capital Deficit -- $200,000, representing a calculation that includes a deferred grant funding liability of $15 million.
• Research and Development Expense -- $200,000, decreasing from $1.4 million in the prior year, partially due to $4.7 million in contra-R&D offsets from nondilutive funding.
• Selling, General and Administrative Expense -- $2.6 million, increasing from $2.4 million primarily reflecting a non-cash write-down of previously deferred offering costs.
• DARE-VVA1 Sildenafil Cream Market Opportunity -- $2 billion, based on an estimated addressable population of 20 million women in the United States experiencing low or no sexual arousal.
• Sildenafil Cream Pricing -- $99 per tube, which is designed to provide approximately 10 uses per prescription.
• Ovaprene Enrollment Target -- 400 to 500 participants, which management expects will achieve at least 2,500 menstrual cycles of exposure in 2027 to support top-line data.
• DARE-HPV Total Funding -- $2 million, following the receipt of a second $1 million tranche from the National Institute of Allergy and Infectious Disease in August 2026.
• DARE-HPV Phase 2 Scale -- 100 women with persistent high-risk infections, with top-line results targeted for 2027.
• Contra-R&D Expense -- $4.7 million, representing grant and governmental funding that reduced direct spending on the Ovaprene and DARE-LARC1 programs.
• Flora Sync LF5 Study Scale -- 100 women, who participated in a randomized clinical study published in a peer-reviewed journal supporting the product.
• Net Loss per Share -- $0.20, compared to $0.45 in the second quarter of 2025, reflecting a higher weighted average share count and lower net loss.
• Total Assets -- $22.4 million as of June 30, 2026, decreasing from $32.5 million at the end of 2025.
• Ovaprene FDA Amendment -- The removal of the 250-completer requirement, which management stated would generate sufficient safety data for a premarket approval submission.
• DARE to PLAY Sildenafil Cream Revenue Timeline -- Expected to commence in the third quarter of 2026, with nationwide prescription intake currently underway through the DARE Health Hub.
• DARE-HRT1 Availability -- Targeted for 2027 via the 503B compounding pathway to address symptomatic needs in menopause hormone therapy.
• Cost of Revenues -- $300,000, primarily associated with R&D services for the Gates Foundation and commercial readiness activities for Sildenafil Cream.

Need a quote from a Motley Fool analyst? Email [email protected]

RISKS

• Johnson noted that the FDA "continued to strongly recommend a minimum of 250 completers and expressed belief that it may be necessary to adequately characterize the safety of Ovaprene," despite the agency approving an amendment to remove that specific requirement from the Phase 3 protocol.

SUMMARY

Daré Bioscience, Inc. (DARE -1.84%) transitioned into a commercial-stage biotech company during the second quarter, highlighted by the launch of its first directly marketed product and the preparation for a second launch in the third quarter of 2026. Management reported a narrowing net loss and a significant reduction in net research and development expenses, which was driven by $4.7 million in nondilutive funding and contra-R&D offsets. The company focused on establishing a digital commercial infrastructure, centered on the DARE Health Hub, to facilitate consumer access to science-backed vaginal and sexual health solutions. Strategic progress also included positive interim safety reviews for its pivotal contraceptive trial and the initiation of a Phase 2 study for a therapeutic targeting high-risk HPV.

• CEO Johnson stated, "The infrastructure, the relationships, and the capabilities we are putting in place today are designed to support efficient, repeatable growth as our commercial portfolio expands."
• The company entered a strategic collaboration with MyMenopauseRx to connect telehealth patients with perimenopause and menopause care providers exploring sexual health solutions.
• Management reported that Flora Sync LF5 was formulated with a proprietary strain of lactobacillus fermentum LF5 backed by three decades of research.
• The company utilizes a dual path regulatory strategy for its topical sildenafil cream, employing 503B compounding for near-term market entry while pursuing a 505(b)(2) application for FDA approval.
• Management noted that clinicians reported a market shortage of estrogen patches, which may drive demand for the company's DARE-HRT1 intravaginal ring that delivers both estradiol and progesterone.

INDUSTRY GLOSSARY

• 503B Compounding: The production and supply of drug products by outsourcing facilities registered with the FDA that are permitted to compound drugs without patient-specific prescriptions under current Good Manufacturing Practice regulations.
• 505(b)(2): A regulatory pathway that allows an applicant to rely on existing safety and efficacy data for an approved drug to support a new drug application.
• Contra-R&D Expense: Amounts received under grant and governmental funding awards that reduce reported research and development expenses as related costs are incurred.
• HPV: Human papillomavirus, a common infection that can lead to cervical intraepithelial neoplasia and other pathologies.
• Ovaprene: An investigational hormone-free monthly intravaginal contraceptive currently in a pivotal Phase 3 study.
• XACIATO: A lincosamide antibacterial gel approved for the treatment of bacterial vaginosis in females 12 years of age and older.

Full Conference Call Transcript

Operator: Hello. And welcome to the Dare Bioscience Second Quarter 26 Corporate Update Conference Call and Webcast. As a brief reminder, all participants are in a listen-only mode. Following the presentation, there will be a question-and-answer session. Note that this webcast is being recorded at the company's request and a replay will be made available on the company's website following the end of the event. Joining us today from Dare Bioscience are Sabrina Martucci Johnson, president and chief executive officer, and MarDee J. Haring-Layton, chief accounting officer. Ms. Haring-Layton, please proceed.

MarDee J. Haring-Layton: Good afternoon, and welcome. Today, we will review our financial results, provide updates on our commercial products and clinical pipeline and discuss the continued execution of our expanded business. That strategy includes a dual path approach, commercializing proprietary formulations through 503D compounding while pursuing FDA approval and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women's health solutions to market as efficiently and quickly as possible. Would like to remind you that today's discussion will include forward looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 2000.

Any statements made during this call that are not actual statements of historical facts should be considered forward looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward looking statements. Forward looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our quarterly report on Form 10 Q for the quarter ended 06/30/2026, which was filed today, and our annual report on Form 10-K for the year ended 12/31/2025. Please note that the content of this call includes time sensitive information that is current only as of today, 08/13/2026.

Dare undertakes no obligation to update any forward looking statements to reflect new information or developments after this call, except as required by law. I would also like to point out that when we use the term 503B compounding during this discussion, we are referring to compounding drug products by outsourcing facilities registered under section 503B of the federal Food, Drug, and Cosmetic Act using both drug substances on the FDA's interim category 1 list. I would now like to turn the call over to Sabrina.

Sabrina Martucci Johnson: Thank you, MarDee, and good afternoon, everyone, and thank you for joining us. For more than 10 years, Dare has been building toward this moment. We built Dare on a simple conviction, Women's health is an investment grade category. Not a niche, not a side project. A category worth building, funding, and holding accountable for delivering the healthcare options women deserve, Every asset we developed, every trial we ran, every grant we secured, every collaboration we have negotiated, all of it has been directed toward this 1 purpose. Closing the gap between promising science and real world solutions for women. And over the past few months, that strategy crossed an important threshold.

We did not stop being a science driven development company. We added something new. Commercial execution and that distinction matters. Dare was built not only to develop differentiated solutions for women's health, but to bring those solutions directly to the women who need them. With our first product that we are commercializing directly now on the market, and a second, approaching prescription dispensing. That vision is becoming a commercial reality. In June, we launched Flora Sync LF5. The first product in our RESTORE line. It was Dare's first product to enter the market directly via Dare. And a milestone marking a new chapter for our company. At the same time, we continued advancing DARE-VVA1 Sildenafil Cream toward prescription dispensing.

Which we are targeting to begin this quarter. 1 product is launched, and a second product is approaching dispensing. And a commercial platform is now live. And that is what makes this quarter different. We are still in the early stages of commercialization, and our priority is disciplined execution. The infrastructure, the relationships, and the capabilities we are putting in place today are designed to support efficient, repeatable growth as our commercial portfolio expands. The transition is real, Dare now has products moving from pipeline into the market and a strategy designed so that each launch strengthens that platform for the next So let me begin with Flora Sync LF5.

Flora Sync LF5 is a non hormonal probiotic vaginal capsule designed to support vaginal microbiome balance. Moisture, and comfort. Available without a prescription, it is formulated with a form of lactobacillus fermentum LF5, a proprietary strain backed by more than 30 years of probiotic research. What differentiates Flora Sync LF5 is the science behind it. Flora Sync LF5 is evaluated in a randomized clinical study involving 100 women. With results published in a peer reviewed journal. That level of product specific clinical research is unusual in a category where consumers frequently encounter products with limited supporting evidence. And we believe this creates a meaningful commercial opportunity.

1 survey found that approximately 65% of women aged 18 to 65 feel insecure about their vaginal scent. Flora Sync LF5 does not need to reach the entire market to become a meaningful product for Dare. Even modest penetration could generate significant commercial value particularly when considering the potential for repeat use. Flora Sync LF5 was priced with accessibility, and ongoing use in mind. We believe it has potential to become part of a woman's regular vaginal care routine. Creating an opportunity to drive initial trial, encourage recurring demand, and build lasting consumer relationships. Let me now turn to DARE-VVA1 Sildenafil Cream, our proprietary topical Sildenafil Cream designed for women.

Which addresses a large and deeply underserved area of women's health. An estimated 20 million women in The United States experience symptoms of low or no sexual arousal. Yet there is no currently FDA approved treatment specifically indicated for female sexual arousal disorder. Women have waited far too long for solutions developed around their experiences, and needs. In clinical studies of our formulation, we observed increased genital blood flow and improvements in arousal sensations. The formulation was well tolerated by both users and their partners in our Phase 2b study. And no serious safety concerns were reported. By improving physical arousal sensation, DARE-VVA1 Sildenafil Cream is designed to support a more positive and responsive sexual experience.

At a price of $99 per tube, which provides for about 10 uses the estimated addressable population of 20 million women represents a total market opportunity of approximately $2 billion Even modest market penetration could create meaningful commercial value in an area with limited female specific treatment options. Initially, we intended to make DARE-VVA1 Sildenafil Cream available by prescription as a 503B compounded product. While continuing to pursue the 505B2 regulatory pathway toward potential FDA approval. Now you might ask, why the dual path regulatory strategy? And the reason is that while the compounded pathway offers a capital efficient way to enter the market, FDA approval would represent an opportunity for women to have an FDA approved option.

As men do, An FDA approved product could provide greater confidence among patients and prescribers and to more support broader commercial adoption because FDA approved products can be administered as treatments and considered for coverage by payers. It can also strengthen our competitive position to create a more durable and valuable commercial franchise. And in this way, the compounded product can provide an efficient path to early market entry, while pursuing FDA approval is designed to unlock the potential of the product as the potential first FDA approved product for female sexual arousal disorder. Although DARE-VVA1 Sildenafil Cream is not yet dispensing, interested customers can already begin the simple process of obtaining a prescription.

While it is still early, I am encouraged by what we are seeing in terms of geography of prescriptions being written, a healthy split between office providers and telehealth, and repeat prescriptions from providers. Dispensing is targeted to begin this quarter. Let's now turn to our commercial strategy. It begins with providers. OBGYNs and women's health specialists are trusted voices and their conviction can drive both product awareness and appropriate patient use. Digital marketing expands that reach by educating women directly and helping us identify the messages and audience that converts most efficiently. Telehealth creates convenient access and national reach. And the DARE Health Hub brings education, product access, fulfillment, and ongoing engagement into 1 central destination.

Our recently announced collaboration with MyMenopauseRx further expands that ecosystem through an established women's health telehealth platform. Additionally, this collaboration highlights how we plan to engage with other telehealth platforms where women can receive a prescription for DARE-VVA1 Sildenafil Cream. And the Dare Health Hub serves as the foundation of our commercial strategy. For patients, the Dare Health hub creates a central destination where women can learn about our products, understand which solutions may be relevant to their needs, and navigate the path to access. It brings together education, product discovery, telehealth connectivity, fulfillment, and ongoing engagement in a convenient and cohesive experience. For Dare, the Dare Health Hub creates a direct connection with the women we serve.

It gives us greater visibility into the full customer journey, from initial awareness and product evaluation through purchase, fulfillment, repeat use, and engagement with additional products across our portfolio. The Dare Health Hub also allowed us to maintain that relationship beyond a 1-time transaction. As women return for information, additional support, or repeat purchases, we have the opportunity to build trust deepen engagement, and introduce other Dare products that may address their needs at different stages of life. As our portfolio grows from vaginal health to sexual health and over time, menopause, each product can benefit from the same digital infrastructure, provider relationships, and expanding customer base.

We believe that shared foundation can make each successive launch more efficient while increasing the long term value of the platform as a whole. We are also building awareness through trusted voices in women's health. Podcasts, clinician conversations, and influencer interviews allow us to engage women in credible, relevant settings where they are already seeking information about their health. These channels help translate awareness into action by educating women introducing them to Dare products, and creating clear pathways into the Dare ecosystem.

To add, these conversations have also reinforced the need we set out to address We are hearing firsthand that women are actively seeking solutions developed specifically for them and they want better information greater access, and credible options they can trust. That response has been encouraging, and it validates both the products we are bringing forward and the commercial approach that we are building around them. And that brings me to how we will evaluate performance during the early launch period. We are focused on 3 primary groups of commercial indicators. Each designed to give us a clear view of how demand is developing where we are seeing the strongest opportunities to scale. The 1st is consumer adoption.

Initial interest is important. But the stronger measure is whether that interest converts into a purchase and whether a positive initial experience leads to recurring demand. These indicators will help us understand who our customers are how they discover our products, and what drives them to return. The 2nd is provider adoption. Providers play an important role in establishing credibility and connecting women with appropriate solutions. Initial provider trial is a positive 1st step, but consistent prescribing, recommending, and stocking will be indicators that our products are becoming part of routine clinical practice. And the 3rd is commercial efficiency.

Which will help us determine which channels are producing the strongest results where additional investment is warranted and how effectively we are translating commercial spending into sustained customer demand. Taken together, these indicators will provide a comprehensive view of adoption customer behavior, the efficiency of our commercial model. For 2026, our objective is disciplined execution and commercial validation. We are establishing the performance benchmarks customer relationships, and repeatable processes needed to support stronger and more efficient growth in 2027 and beyond. I would now like to highlight several of our other programs where we have made important progress recently. Ovaprene, our investigation hormone free monthly intravaginal contraceptive continues to advance through its pivotal Phase III study.

During the quarter, we reported positive interim results and the independent Data Safety Monitoring Board recommended that the study continue without modification. We expect to enroll sufficient subjects in 2026 to achieve at least 2.5 thousand menstrual cycles of exposure in 2027. Supporting a top line data announcement in 2027. We expect to complete enrollment with between 400 to 500 participants, but less than 250 completers, which was the original FDA requested target. In August 2026 this year, the FDA approved our proposed amendment to remove the expectation of 250 completers.

While in this approval, the FDA continued to strongly recommend a minimum of 250 completers and expressed belief that it may be necessary to adequately characterize the safety of Ovaprene Based on the interim safety data reviewed by the DSMB, including the absence of new types of adverse events or increased frequency of adverse events with prolonged use, and the study's expected achievement of at least 2.5 thousand menstrual cycles of exposure, we believe the amended protocol will generate sufficient safety data to support a premarket approval submission.

We plan to continue to engage with the FDA at this point, with no FDA approved monthly hormone free intravaginal contraceptive currently available, Ovaprene has the potential to offer women an important new option in a category where meaningful innovation remains limited. We also initiated a Phase II study of DARE-HPV1 and that is expected to enroll approximately 100 women with persistent high risk HPV infection. With top line results expected in 2027. The phase 2 study is supported by a contract funded by ARPA-H. During the quarter, in addition to the funding under the contract through ARPA-H, we also received a funding award notice for a second $1 million tranche from the NIAID.

Bringing the total funding across the project period that began in December 2024 to $2 million. DARE-HRT1 estradiol progesterone intravaginal ring represents another important opportunity. Activities to support commercial availability through 503B compounding pathway are underway with dispensing targeted to begin in 2027. Turning to our earlier stage pipeline, these programs extend across contraception, pelvic pain, preterm birth, and other areas where women continue to face significant unmet needs and represent multiple opportunities to expand our commercial portfolio and create value over time. Importantly, we are advancing many of these programs through collaborations and non dilutive funding.

Our NIH and Gates Foundation funding contracts as well as relationships with organizations including Theramex, the University of Copenhagen, and Australia's research and development incentive program allowed us to access external expertise and capital while maintaining a disciplined approach to investment. I would now like to hand the call back over to Mark for a financial update.

MarDee J. Haring-Layton: Thank you, Sabrina. We ended the quarter with approximately $12.6 million in cash and cash equivalents as of 06/30/2026, and a working capital deficit of approximately $200 thousand. Our working capital is calculated as current assets less current liabilities, which included a deferred grant funding liability of approximately $15 million Total revenue for the second quarter was $200 thousand compared with approximately -$21 thousand in the same period last year. As you recall from last year, we had an accounting adjustment related to Vagisil royalties. Revenue for the second quarter of 2026 consisted solely of research and development services and royalty revenue.

Because Flora Sync LF5 sales began in July, our second quarter results do not include revenue from that product. Selling, general and administrative expenses were approximately $2.6 million compared with approximately $2.4 million in the second quarter of 2025. The increase primarily reflects a noncash write down of previously deferred offering costs. Along with investments in personnel and commercial readiness activities supporting our expanded business strategy. These increases were partially offset by lower professional services and stock based compensation expenses. Research and development expense decreased to approximately $200 thousand from approximately $1.4 million in the prior year period.

The decrease reflects significant contra-R&D expense associated with non dilutive funding that offset direct program costs as well as lower spending across several programs. This demonstrates the value of our nondilutive funding and our continued focus on disciplined capital allocation. Net loss for the quarter improved to approximately $3 million compared with a loss of approximately $4 million in the prior year period. Looking ahead, we began recording revenue from Flora Sync LF5 sales in July and expect to begin recording revenue from DARE-VVA1 Sildenafil Cream in the third quarter. With revenue from DARE-HRT1 estradiol, progesterone, IVR targeted to begin in 2027, we are building toward a diversified multi product revenue profile across 2026 and 2027.

As always, I encourage investors to review our quarterly report Form 10 Q filed today with the SEC for a more detailed discussion of our financial results, liquidity, and capital resources and risk factors. Back to you, Sabrina.

Sabrina Martucci Johnson: Thank you, Mark. Dare is entering an important new phase in its evolution commercial execution underway and multiple opportunities to create value across the portfolio. We now have our first directly commercialized product on the market. And DARE-VVA1 Sildenafil Cream is approaching prescription dispensing and a commercial platform designed to support the products that follow. This is the foundation of a scalable multiproduct business focused exclusively on addressing significant unmet needs in women's health. And at the same time, our development pipeline continues to advance. Together with our earlier stage programs, these assets provide multiple clinical regulatory, and commercial milestones ahead.

By combining focused commercial investment and strategic collaboration, and meaningful non dilutive funding, we can continue advancing a broad portfolio while directing resources toward the programs and activities with the greatest potential to create value. And what makes this moment different is that the pieces are now coming together. We believe this positions Dare to build commercial momentum reach more women with differentiated solutions, and create meaningful long term value for patients and shareholders. I will now turn the call back to the operator for any questions.

Operator: Thank you. Quick reminder before we start the Q&A. If you would like to ask a question, please press *1 on your telephone keypad to raise your hand and enter the queue. If you would like to withdraw your question or your question has been answered, simply press *1 again. We will pause for just a moment to compile the roster. Thank you. And we will take our first question from Douglas Tsao from H. C. Wainwright. Please go ahead.

Douglas Tsao: Hi, good afternoon. Can you hear me? Yes. Okay. Great. Hi, Sabrina. Thanks, and congrats on the progress. Hi. I guess just maybe as a starting point, think it would be helpful to sort of hear your thoughts on the near term commercial portfolio. So, I mean, FloraThink and Dare2Play, as well as Dare2Reclaim. Just in a lot of ways, when I think with these products, they sort of have very different profiles from an end user and perhaps somewhat have different needs from a sort of promotion standpoint.

And I just I am curious how you sort of think about pulling those together and do you sort of anticipate building a Dare brand, or do you think that these products should have their own brand that sort of stands on their own? Thank you.

Sabrina Martucci Johnson: Yeah. Great question, and thank you for asking about that. And while on the 1 hand, they definitely are different, Right? Flora Sync LF5 is a nonprescription probiotic. DARE-VVA1 Sildenafil Cream is an arousal cream? And it is prescription, and DARE-HRT1, as estradiol, progesterone, intravaginal ring is specifically for menopause. Hormone therapy. So on the 1 hand, yes, there may be overlap between the women using the products, and in some cases, they may be distinct users. But what all the products have in common is that they are all based on clinical evidence, They are all based on credible science.

And they are all products that can be very easily understood and talked about and kind of digested by both women directly but also healthcare providers. And that is really distinct. And so to your question about the Dare brand, we do think the Dare brand is very important because to our knowledge, we remain the only biotech company working broadly and solely across women's health therapeutics to bring solutions like this to market. So we have a very, very strong incredible brand with the healthcare provider community. And we are really leveraging that brand to the consumer. Community as well. And so we do think it is really important.

And in fact, that is why all the products, have Dare, right, which is our ticker symbol, have DARE in the name, and we love that kind of play on words and that opportunity to bring in that way. So in terms of, therefore, the strategy and I talked about this a little bit in the remarks, it really allows us to build awareness through a very focused and measurable approach. Right, that prioritizes whatever channels are most efficient for these consumer campaigns. As well as really focusing on the healthcare provider engagement. And that is, I think, something unique that we can do given the credible science behind our products.

And then making sure that across the portfolio, we are really targeting digital marketing and patient education and leveraging the DARE Hub as that 1 central commercial platform for that. So that we can make sure that we are reaching women that are actively seeking solutions And it also allows us to kind of look at the different channels and allocate capital accordingly. And I think the approach is really working.

What we have seen with DARE-VVA1 Sildenafil Cream, even though it is not dispensing yet, is that, as I mentioned, there is a really nice healthy mix between prescriptions coming in from providers, right, that are writing those prescriptions for patients that they are seeing either in their offices or through their dedicated telehealth practices. But then we are also seeing a really nice mix of women that are going through the telehealth option that we provide on the DARE Hub. So that really means that we are reaching women kind of where they are seeking their information. Right?

If they are getting their information and they are looking for solutions online and directly, they are likely to be using our telehealth option on the DARE Health hub. Or if they already have maybe a trusted healthcare provider resource, you know, it is great to see that those providers are writing as well. So I know that was a long answer to your question, but hopefully that gives you some sense that, you know, there really is a through line between the products, and that through line is that credible science. And that is the Dare brand. And we really think that brand you know, is so important. It is really 1 of the big differentiators for us.

As a company and, importantly, our products for women.

Douglas Tsao: And, Sabrina, do you think that brand is gonna resonate more with clinicians, or do you ultimately see that as a brand that you would like to have resonate with patients?

Sabrina Martucci Johnson: Yeah. Really with both. Really with both. And so you know, we have those established relationships across the women's healthcare community. So, obviously, that is been a place we have been able to lean into right away. And then we have been using those relationships obviously, to educate providers and have them educate each other. And they are definitely a trusted source for women. But we can also leverage those same relationships through those influencer providers, right, trusted sources, of information online so that we can build our brand directly with women.

And, obviously, the providers know us today, already, and we are building that brand with women through a lot of these initiatives that are going live right now that we talked about.

Douglas Tsao: Okay. that is very helpful. And if I can, just 1 more question on DARE-HRT1. Because I think that is a product opportunity that is, you know, not that far away but has a lot of tailwinds going forward, in particular, some of the regulatory action in terms of removing sort of warnings around hormone replacement therapy, And, you know, obviously, there are a lot of millions of scripts written for hormone replacement therapy. Every year.

Sabrina Martucci Johnson: Yes. How do you sort of think about converting them from sort of often compounded products, oral products, etcetera, to dare to reclaim. Thank you.

Douglas Tsao: Thank you for asking about that, by the way.

Sabrina Martucci Johnson: I love talking about this product, and I know I did not talk about it so much in the opening remarks because they are obviously so focused on what is happening today. But as you mentioned, this is something we are targeting to be on market in 2027. And I think the best way to describe how we are thinking about it and how the healthcare provider community is thinking about it is I just had a call a little bit ago with 1 of the clinicians that was very instrumental and has been very much seen in all the press and talk about removing the black box warning from the hormone therapy products.

And you know, she is just she cannot wait for Dairy Queen to be available because as she keeps reminding me, they just do not have anything like this available today. With the clinical evidence that we are generating the pharmacokinetic levels of both estradiol for it is basically what is going to resolve the symptoms and the progesterone, which is there for endometrial safety, that have been demonstrated through pharmacokinetics to be the levels that are needed. And in a non oral form, and it is clinically studied.

And so, you know, she keeps highlighting, my gosh. cannot you go faster? there is a shortage of patches, and, you know, we are we are cobbling together these care solutions for our patients. Of patches for the estrogen and some other dosing regimen for the progesterone. and it is cumbersome, and it is clunky. So, yeah, we are we are super excited. And I think, again, this is 1 where the product is gonna do the work. The product's already done the work. To demonstrate the pharmacokinetics, to demonstrate the data. You know, the product has been responsive to what the menopause society and the medical community have been asking for.

And so we definitely think this is 1 where the product is going to do, you know, the heavy lift in terms of moving patients, moving women from something that is not as easy to use, that is not as convenient, and does not follow the recommendations of the menopause society in such a clear way, to a product that does. So we cannot move fast enough on this 1. Yep. Thank you, Douglas. Thank you.

Operator: We have reached the end of the Q&A session. I will now turn the call back over to Sabrina Martucci Johnson for closing remarks.

Sabrina Martucci Johnson: Great. Well, thank you so much. And as we close, I really want to take another moment to share how excited we are here at Dare We have worked for years to develop solutions that address meaningful gaps in women's health. And it is incredibly rewarding to see that work reaching women while our broader portfolio continues to advance. We believe this is the beginning of an important new chapter for Dare, and we look forward to sharing our continued progress with you.

Operator: The meeting has now concluded. Thank you all for joining this conference and you may now disconnect.